Global Monoclonal Antibody Medicine Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Monoclonal Antibody Medicine Market Research Report 2024
Monoclonal antibodies are immune system proteins that are created in the lab. Antibodies are produced naturally by your body and help the immune system recognize germs that cause disease, such as bacteria and viruses, and mark them for destruction. Like your body’s own antibodies, monoclonal antibodies recognize specific targets.
According to Mr Accuracy reports’s new survey, global Monoclonal Antibody Medicine market is projected to reach US$ 460510 million in 2029, increasing from US$ 216310 million in 2022, with the CAGR of 12.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Monoclonal Antibody Medicine market research.
The monoclonal antibody medicine market is driven by the growing demand for targeted and personalized therapies and the significant advancements in biotechnology and antibody engineering. Monoclonal antibodies (mAbs) offer precise targeting of specific antigens, making them highly effective in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Their ability to modulate the immune response and their potential for fewer side effects compared to traditional treatments have fueled their popularity among healthcare providers and patients. Moreover, the development of novel mAbs and the expansion of approved indications for existing therapies further contribute to market growth. However, the market also faces challenges, including the high cost of mAb therapies, which can limit patient access and reimbursement. Additionally, the complex manufacturing process and regulatory requirements for mAb medicines can be obstacles for new market entrants. To succeed in this competitive market, manufacturers must focus on improving affordability, exploring biosimilar opportunities, and investing in research and development to develop innovative and differentiated monoclonal antibody medicines that address unmet medical needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Monoclonal Antibody Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Innovent Biologics
Segment by Type
Biologics
Biosimilars
Cancer
Autoimmune Disease
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Monoclonal Antibody Medicine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Monoclonal Antibody Medicine market is projected to reach US$ 460510 million in 2029, increasing from US$ 216310 million in 2022, with the CAGR of 12.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Monoclonal Antibody Medicine market research.
The monoclonal antibody medicine market is driven by the growing demand for targeted and personalized therapies and the significant advancements in biotechnology and antibody engineering. Monoclonal antibodies (mAbs) offer precise targeting of specific antigens, making them highly effective in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Their ability to modulate the immune response and their potential for fewer side effects compared to traditional treatments have fueled their popularity among healthcare providers and patients. Moreover, the development of novel mAbs and the expansion of approved indications for existing therapies further contribute to market growth. However, the market also faces challenges, including the high cost of mAb therapies, which can limit patient access and reimbursement. Additionally, the complex manufacturing process and regulatory requirements for mAb medicines can be obstacles for new market entrants. To succeed in this competitive market, manufacturers must focus on improving affordability, exploring biosimilar opportunities, and investing in research and development to develop innovative and differentiated monoclonal antibody medicines that address unmet medical needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Monoclonal Antibody Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Innovent Biologics
Segment by Type
Biologics
Biosimilars
Segment by Application
Cancer
Autoimmune Disease
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Monoclonal Antibody Medicine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
